Welcome to our dedicated page for Juva Life news (Ticker: JUVAF), a resource for investors and traders seeking the latest updates and insights on Juva Life stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Juva Life's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Juva Life's position in the market.
Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) reported strong Q3 2021 results, with revenues soaring by 322% year-over-year to $1.2 million and a significant 390% increase for the nine-month period, totaling $2.5 million. Gross profit for Q3 reached $0.51 million, representing 43.1% of revenue. Additionally, total net expenses decreased from $3.1 million to $2.5 million. The company is expanding its pharmaceutical research initiatives and has nominated JUVA-019 for further study due to its significant anti-inflammatory properties, enhancing its position in the cannabis research sector.
Juva Life Inc. (CSE: JUVA, OTCQB: JUVAF) has initiated a pre-clinical study evaluating the anti-inflammatory properties of its proprietary compound JUVA-019 in combination with cannabinoids like THC and CBD. The study aims to determine whether JUVA-019 is more effective as a standalone treatment or when combined with cannabinoids. Conducted by Dr. Sanjeev Gangwar, the research will focus on IL1-beta and TNF-alpha inhibition. This marks a key step in advancing Juva's pharmaceutical goals, targeting chronic conditions affecting millions globally.
Juva Life Inc. (CSE: JUVA, OTCQB: JUVAF) announced on Nov. 15, 2021, the discovery of JUVA-041, a new non-cannabinoid compound with anti-inflammatory properties, expanding its pharmaceutical pipeline. This follows JUVA-019, another proprietary compound already under patent. The company plans to conduct comparative studies between the two compounds to explore their efficacy and potential combinations. Juva aims to initiate non-clinical development within 6-9 months, enhancing shareholder value through its dual approach of consumer and medical strategies.
On October 14, 2021, Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) announced the advancement of the JUVA-19 class of compounds into formal development. JUVA-19, a non-cannabinoid small molecule from cannabis, shows dose-dependent inhibition of IL1-beta and TNF-alpha, suggesting significant anti-inflammatory properties. Juva aims to leverage its research for consumer and pharmaceutical applications, having filed a provisional patent on relevant methodologies. Additionally, the company appointed Dr. Peter Beitsch to its Board of Directors, enhancing its expertise as it progresses in product development.
Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) announced breakthrough pre-clinical results, identifying Juva-019, a non-cannabinoid compound with broad anti-inflammatory properties. This small molecule targets TNF-alpha, IL-1 beta, and other cytokines linked to inflammation, aiming to enhance drug and consumer product development. Juva is developing a pipeline of bioactives at reduced costs and risks. The company plans to optimize these compounds and may partner with pharmaceutical firms. Additionally, founding board member Rakesh Patel has resigned from the board but will lead the Clinical Advisory Board.
Juva Life Inc. (CSE: JUVA, OTCQB: JUVAF) announces a CEO Livestream event on May 25, 2021, at 5:30 PM PT. This event will feature CEO Doug Chloupek discussing recent developments and answering audience questions. Participants can submit questions through the company website until midnight on May 24. The livestream will also include a presentation from CFO Mat Lee. Viewers can access the event live and post-event via the Juva website and YouTube.
To learn more about Juva Life, visit juvalife.com.
Juva Life Inc. (CSE: JUVA, OTCQB: JUVAF) has announced the sale of a nonessential 11,500 sq. ft. facility in Stockton, California for $1.1 million (USD). This sale allows Juva to focus on its primary 30,000 sq. ft. San Juan facility, where significant progress is being made in cannabis cultivation. The company anticipates its first crop harvest by May 13, 2021. A live presentation is scheduled for May 25, 2021, to discuss business development and commercial activities.
Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) has enrolled its first human subject in the "Natural History of Disease: Cannabis Registry" Clinical Study. This milestone marks the beginning of Juva's endeavor to develop a clinical methodology to assess the effects of cannabis formulations on patients. The study aims to provide evidence for new cannabis-based products targeting conditions like pain and sleep disorders. Initial data collection is set to conclude by Q4 2021, with a study timeline from February 15, 2021, to February 15, 2025.
Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) has commenced commercial cannabis cultivation at its Stockton, California facility. Following state licensing approval, the company has begun planting propagated cannabis clones, aiming for its first harvest within weeks. The goal is to generate 6,000 pounds of premium cannabis annually, with a harvest every twelve days once fully operational. Juva has invested in systems to enhance operational efficiency and reduce costs, projecting a 50% decrease in electrical expenses. This move marks Juva's transition from development to commercial enterprise, with potential increased revenues and future proprietary product development.